Seaport Therapeutics filed terms for a $201 million IPO this week, pricing expected within 72 hours. The Boston-based neuropsychiatric therapeutics company joins a sparse biotech IPO calendar that has seen only four life sciences pricings in the trailing 90 days.

The company is offering 11.8 million shares at a midpoint of $17, placing its post-money valuation near $850 million. Seaport's lead asset, SPN-830, targets major depressive disorder with a rapid-onset oral formulation designed to compete against esketamine nasal spray and legacy SSRIs. Phase 2 data published in October showed statistically significant reduction in MADRS scores at 48 hours, a timeline that matters in acute care settings. The company also holds rights to SPN-812, a non-stimulant ADHD candidate licensed from Supernus Pharmaceuticals under a milestone-based deal that includes $45 million in near-term payments.

The pricing comes as biotech IPO windows compress. Year-to-date life sciences issuance stands at $2.1 billion across 14 deals, down 38% from the same period in 2023. Institutional appetite has narrowed to late-stage assets with visible commercial pathways or platform economics that scale across indications. Seaport sits in the middle: a clinical-stage play with one lead program in Phase 2 and a second asset still under regulatory review for pediatric ADHD. The company burned $62 million in the trailing twelve months and holds $89 million in cash pre-IPO, giving it roughly 18 months of runway at current spend.

What allocators are watching is whether Seaport can attract crossover funds that have largely stayed on the sidelines since the biotech correction of 2022. The IPO syndicate includes Goldman Sachs, Jefferies, and Leerink Partners, all of which have placed similar-sized neuropsychiatry deals in the past 24 months. Pricing discipline will matter. If Seaport prices at or above midpoint, it signals that institutional buyers see differentiation in the rapid-onset depression mechanism. If it prices below $16, the market is treating this as a binary Phase 3 bet with limited visibility.

The broader context is that psychiatric therapeutics are seeing renewed capital interest after years of clinical failures. Johnson & Johnson's Spravato generated $1.05 billion in 2023 sales, proving commercial viability for faster-acting depression treatments. Axsome Therapeutics trades at $79, up 110% from its 2023 lows, after back-to-back approvals in depression and migraine. Seaport is positioning itself as the next wave, but it enters a market where differentiation is hard and reimbursement fights are long.

Operators should track three things: whether Seaport prices in the top half of its range by end of week, whether the stock holds its debut price through the first 10 trading days, and whether the company announces a Phase 3 trial start for SPN-830 within six months. That last point is the real signal. No Phase 3, no institutional follow-on. Biotech windows close faster than they open, and Seaport has roughly $200 million in new cash to prove it can reach a pivotal dataset before the next fundraise.